World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
79958
World Ranking
2197
National Ranking
233

Overview

Robert E. Coleman is affiliated with the University of Sheffield in the United Kingdom. Their research focuses primarily on medicine, with significant contributions to subfields such as oncology, radiology, nuclear medicine and imaging, cancer research, pulmonary and respiratory medicine, and surgery.

The scientist has published extensively on topics related to bone health and treatments, radiopharmaceutical chemistry and applications, cancer diagnosis and treatment, breast cancer treatment studies, management of metastatic bone disease, bone health and osteoporosis research, and estrogen and related hormone effects.

Frequent publication venues for their work include the Journal of Bone Oncology, The Lancet Oncology, Cancer Research, Annals of Oncology, and JAMA Oncology.

Some of Robert E. Coleman's recent papers include:

  • Bone metastases, 2020, Nature Reviews Disease Primers
  • Bone health in cancer: ESMO Clinical Practice Guidelines, 2020, Annals of Oncology
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials, 2023, The Lancet
  • POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes, 2021, BMJ Open

The scientist frequently collaborates with other researchers including Janet E. Brown, David Dodwell, David Cameron, Judith M. Bliss, and Jack Cuzick.

Best Publications

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle

  • Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

    Robert E. Coleman

  • A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

    R. C Coombes;E. Hall;L. J. Gibson;R. Paridaens

  • Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

    R.E. Coleman

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • The clinical course of bone metastases from breast cancer.

    RE Coleman;RD Rubens

  • Adjuvant docetaxel for node-positive breast cancer.

    Miguel Martin;Tadeusz Pienkowski;John R Mackey;Marek Pawlicki

  • Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

    Lee S. Rosen;David Gordon;Mary Kaminski;Anthony Howell

  • Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

    Lee S Rosen;David Gordon;Mary Kaminski;Anthony Howell

  • Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    RC Coombes;LS Kilburn;CF Snowdon;R Paridaens

  • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.

    Matthew R Smith;Fred Saad;Robert Coleman;Neal Shore

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

    W ten Bokkel Huinink;M Gore;J Carmichael;A Gordon

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

    Paul Vasey;Gordon C Jayson;Alan Gordon;Hani Gabra

  • Pathologic fractures correlate with reduced survival in patients with malignant bone disease.

    Fred Saad;Allan Lipton;Richard Cook;Yin Miao Chen

  • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

    Jean Jacques Body;Thierry Facon;Robert E. Coleman;Allan Lipton

  • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study

    James R. Berenson;Lee S. Rosen;Anthony Howell;Lester Porter

  • Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors

    Janet E. Brown;Richard J. Cook;Pierre Major;Pierre Major;Allan Lipton

Frequent Co-Authors

Allan Lipton
Allan Lipton Penn State Milton S. Hershey Medical Center
Richard J. Cook
Richard J. Cook University of Waterloo
Jean-Jacques Body
Jean-Jacques Body Université Libre de Bruxelles
Chris Parker
Chris Parker Institute of Cancer Research
Fred Saad
Fred Saad University of Montreal
Anthony Howell
Anthony Howell University of Manchester
Matthew R. Smith
Matthew R. Smith Harvard University
Judith M. Bliss
Judith M. Bliss Institute of Cancer Research
Walter M Gregory
Walter M Gregory University of Leeds
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medical careers beyond traditional MD paths, there are many flexible options available online. A popular route is pharmacy, where pharm d online programs let students earn a Doctor of Pharmacy from accredited institutions, preparing for vital roles in patient care and medication management.

For those passionate about healthcare data and technology, an online mhi (Master’s in Health Information) can be an excellent choice, opening doors to health informatics and hospital administration roles.

If you are looking for a quicker entry into the healthcare workforce, exploring medical billing and coding cost will help you understand the affordable online certificate programs that can launch careers in medical administration and insurance processing.

Finally, those seeking advanced clinical responsibilities might consider affordable online fnp programs. These pathways allow registered nurses to become certified Family Nurse Practitioners, often with online coursework and flexible schedules.

Each of these degrees supports growing healthcare fields, offering online convenience and diverse career opportunities within the medical sector.

Best Scientists Citing Robert E. Coleman

Trending Scientists

Recently Published Articles